Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study.
Alexandra DrakakiThomas PowlesAristotelis BamiasJuan Martín-LiberalSang Joon ShinTerence W FriedlanderDiego TosiChandler ParkCarlos Alberto Gomez RocaFlorence Joly LobbedezDaniel CastellanoRafael Morales-BarreraIrene Moreno-CandilejoAude FlechonKobe YuenDeepali RishipathakKelly DuPreeFiona YoungFrancesca MichielinColby S ShemeshElizabeth E SteinbergPatrick WilliamsJae Lyun LeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The evaluated regimens in MORPHEUS-UC were tolerable. However, response rates for the combinations did not meet the criteria for further development in platinum-experienced locally advanced or mUC.
Keyphrases
- open label
- locally advanced
- squamous cell carcinoma
- phase iii
- phase ii
- phase ii study
- clinical trial
- rheumatoid arthritis
- small cell lung cancer
- double blind
- neoadjuvant chemotherapy
- study protocol
- placebo controlled
- randomized controlled trial
- radiation therapy
- juvenile idiopathic arthritis
- systematic review
- rheumatoid arthritis patients
- lymph node
- meta analyses